Health
Neoadjuvant combination immunotherapy improves outcomes for early stage non-small cell lung cancer – Medical Xpress
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung…
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory. Researchers from The University of Texas MD Anderson Cancer Center published the study results today in Nature Medicine.
The NEOSTAR…
-
Noosa News21 hours agoHow Lily Steele-Park took her rapist to court and won
-
Noosa News24 hours agoStar’s Brisbane casino has been in the headlines for months: What’s the latest?
-
Business23 hours ago5 things to watch on the ASX 200 on Tuesday 8 July 2025
-
Noosa News21 hours agoE-biker charged with riding dangerously, assaulting cop